EP08.02. Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Nicole Pringle
Meta Tag
Speaker Nicole Pringle
Topic Local-Regional NSCLC: Multimodality Therapy
stage III non-small cell lung cancer
consolidation Durvalumab therapy
retrospective audit
electronic medical records
baseline characteristics
progression-free survival
overall survival
adverse events
real-world clinical practice
Powered By